Northwire Canada EditionFriday, July 10, 2026
Sign inSubscribe
Northwire
⌕
NNX 0.035 +0.0% ABX 51.85 −0.7% TTS 2.50 +0.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 22.99 +10.5% TUNG 1.72 +1.8% LGO 1.00 −3.9% EMM 0.080 +0.0% OGN 3.45 +2.1% MSA 6.40 −0.5% SGZ 0.045 +0.0% S 0.155 +29.2% GRSL 0.310 −3.1% DEX 0.390 +1.3% WMS 0.040 +0.0% NNX 0.035 +0.0% ABX 51.85 −0.7% TTS 2.50 +0.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 22.99 +10.5% TUNG 1.72 +1.8% LGO 1.00 −3.9% EMM 0.080 +0.0% OGN 3.45 +2.1% MSA 6.40 −0.5% SGZ 0.045 +0.0% S 0.155 +29.2% GRSL 0.310 −3.1% DEX 0.390 +1.3% WMS 0.040 +0.0%
M&A / Property Routine +

Helus Pharma Partners with TARA Mind to Advance Veteran Mental Health

Leadership Transition and Recruitment Partnership

By The Northwire Desk — AI Analysis Apr 28, 2026 · 07:30 HELP · 7.36 Contakt World Technologies Corp.
Executive Summary
  • The most recent release (April 28, 2026) details a partnership between Helus Pharma, TARA Mind, and Veterans Exploring Treatment Solutions (VETS).
  • The collaboration aims to support recruitment for the Phase 3 clinical trial of HLP003 (PARADIGM program) targeting Major Depressive Disorder (MDD).
  • This initiative aligns with an April 18, 2026 Executive Order accelerating medical treatments for serious mental illness.
  • Previous news (April 20, 2026) indicates a significant leadership change where Michael Cola stepped down as CEO and Eric So resumed the role as Interim CEO.
  • Earlier data (March 5, 2026) confirmed positive Phase 2 signal detection results for HLP004 in Generalized Anxiety Disorder (GAD).
  • Financials from Q3 FY2026 (Dec 31, 2025) showed a cash position of $195.1 million with an operating burn rate of approximately $31.9 million per quarter.
Material Impact
  • The April 28 partnership is operationally positive but does not constitute a material shift in valuation or fundamental risk profile compared to the recent CEO turnover.
  • Recruitment support for Phase 3 trials is expected progress rather than unexpected market-moving news; it mitigates potential timeline delays but does not guarantee clinical success.
  • The leadership transition (April 20) remains the dominant narrative driver, creating uncertainty that this partnership alone cannot fully resolve.
  • No new financing or capital raise was announced in the most recent release, preserving the current cash runway status.
  • The news is consistent with previous expectations regarding Phase 3 trial execution and regulatory alignment but lacks the magnitude to be classified as Material Positive.
HELP · Price
Company Overview
  • Company Name: Helus Pharma Inc. (formerly Cybin Inc.).
  • Flagship Project: HLP003, a proprietary novel serotonergic agonist (NSA) in Phase 3 development for Major Depressive Disorder (MDD).
  • Designation: HLP003 holds FDA Breakthrough Therapy designation.
  • Secondary Pipeline: HLP004 is in Phase 2 development for Generalized Anxiety Disorder (GAD), with positive signal detection data released March 2026.
  • Mechanism: Focus on short-acting serotonergic agonists designed to activate serotonin pathways and promote neuroplasticity.
Read the original news release →

More from Contakt World Technologies Corp.

Jun 29, 2026 · 07:40

Helus Pharma burns cash faster in Phase 3 ramp but secures $50M runway as HLP003 nears topline readout

Earnings Jun 25, 2026 · 19:03

Helus Pharma closes $50M equity offering to fund Phase 3 MDD readout in Q4 2026, extending cash runway amid leadership transition.

Financings Jun 24, 2026 · 06:01

Helus Pharma(TM) Announces US$50 Million Underwritten Offering

Financings Jun 24, 2026 · 06:00

Helus Pharma Provides Update on APPROACH Phase 3 Trial Enrollment Progress

Regulatory Apr 20, 2026 · 08:15

Management Instability Clouds Near-Term Catalysts Despite Strong Cash Position

Regulatory Apr 20, 2026 · 08:00

Tagline: Leadership Turmoil Overshadows Clinical Wins as Helus Pharma CEO Departs Ahead of Pivotal Phase 3 Readout

Management